poisar

Stocks · News reference

8-K filing — NextCure, Inc. (NXTC)

SEC EDGARSEC EDGAR

Filed: 2026-07-14 AccNo: 0001104659-26-083326 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.05: Cost Associated with Exit or Disposal Activities Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaBenzinga Newsdesk

    NextCure Q2 EPS $(2.80) Misses $(1.94) Estimate

    NextCure (NASDAQ:NXTC) reported quarterly losses of $(2.80) per share which missed the analyst consensus estimate of $(1.94) by 45.08 percent. This is a 75.2 percent increase over losses of $(11.29) per share from the